# Literature Gap Analysis — Enriched Interpreted Report
**Generated:** 2026-04-03 (enriched from script output of same date)
**Source:** PubMed E-utilities API (esearch.fcgi)
**Date range:** 2020/01/01 to 2026/04/03
**Domains analyzed:** 30
**Pairs analyzed:** 435

---

## Methodology

This analysis queries PubMed for publication counts across 30 diabetes research domains, both individually and as pairwise combinations (435 pairs). The **Gap Score** measures how much less cross-domain work exists compared to what each domain's individual activity would predict.

**Formula:** `Gap Score = max(0, 1 - (joint_publications / geometric_mean(domain1_count, domain2_count))) × 100`

**Interpretation:** A Gap Score of 95 means the intersection has 95% fewer publications than the geometric mean of the two domains' individual counts.

**Important caveats:**
- PubMed search matching is approximate (keyword-based, not exact MeSH)
- Low co-publication may indicate: (a) genuinely unexplored territory, (b) terminology mismatch, (c) research under different keywords, or (d) methodologically distinct fields
- Cross-reference with domain expert knowledge before drawing conclusions
- All gap classifications below are labeled with confidence levels per the Research Doctrine

---

## Potentially Meaningful Research Gaps

These domain pairs have low co-publication rates **and** plausible scientific reasons why cross-domain work could yield new insights. These represent the highest-value opportunities for computational contribution.

**Validation level: BRONZE** (single analytical source; requires expert confirmation)

| Rank | Domain 1 | Domain 2 | Gap Score | Joint Pubs | Expected | Rationale | Tier 1 Alignment |
|------|----------|----------|-----------|------------|----------|-----------|-------------------|
| 1 | Beta Cell Regen | Health Equity | 100.0 | 0 | 1,603 | Regenerative therapies must address access. Equity analysis of emerging cell therapies is absent. | Epidemiological Data Analysis |
| 2 | Insulin Resistance | Islet Transplant | 100.0 | 1 | 2,116 | IR in transplant recipients affects graft survival, but this interaction is barely studied. | Literature Synthesis |
| 3 | Islet Transplant | Drug Repurposing | 100.0 | 0 | 369 | Existing immunosuppressants could be repurposed for islet protection. Computational screening not applied. | Drug Repurposing Screening |
| 4 | Islet Transplant | Health Equity | 100.0 | 0 | 665 | Islet transplant available at select centers only. Access equity research absent. | Epidemiological Data Analysis |
| 5 | Gene Therapy | LADA | 100.0 | 0 | 1,075 | LADA's autoimmune mechanism makes it a gene therapy candidate, but no crossover work exists. | Literature Synthesis |
| 6 | Treg / CAR-T | Neuropathy | 100.0 | 0 | 1,615 | Immune-mediated neuropathy could benefit from Treg modulation. No bridging work. **NEW:** NCT07142252 (Rezpegaldesleukin) now recruiting — may generate data here. | Literature Synthesis |
| 7 | Treg / CAR-T | Health Equity | 100.0 | 0 | 1,272 | Advanced immunotherapies risk widening disparities. No equity analysis of CAR-Treg access exists. | Epidemiological Data Analysis |
| 8 | Glucokinase | Drug Repurposing | 100.0 | 0 | 685 | Systematic screening for existing drugs with GK activity is unexplored. | Drug Repurposing Screening |
| 9 | Glucokinase | Health Equity | 100.0 | 0 | 1,234 | If GK activators succeed, global access will be critical. No equity analysis for this drug class. | Epidemiological Data Analysis |
| 10 | Glucokinase | LADA | 100.0 | 0 | 667 | GK role in LADA unstudied despite relevance to residual beta cell function. | Literature Synthesis |
| 11 | Personalized Nutr | LADA | 100.0 | 0 | 565 | LADA patients receive generic T2D dietary advice. Personalized nutrition based on autoimmune status unexplored. | Literature Synthesis |
| 12 | Drug Repurposing | Health Equity | 100.0 | 0 | 1,027 | Repurposing could yield affordable treatments for underserved populations. Equity absent from repurposing research. | Epidemiological Data Analysis + Drug Repurposing |
| 13 | Drug Repurposing | LADA | 100.0 | 0 | 555 | LADA treated with suboptimal T2D drugs. Systematic repurposing for LADA-specific therapies doesn't exist. | Drug Repurposing Screening |
| 14 | Health Equity | LADA | 100.0 | 0 | 1,001 | LADA massively underdiagnosed, especially in minority populations. Equity-focused screening absent. | Epidemiological Data Analysis |
| 15 | SGLT2 Inhibitors | Personalized Nutr | 100.0 | 1 | 2,021 | SGLT2i dietary interactions are unexplored. Nutritional optimization alongside SGLT2i could improve outcomes. | Literature Synthesis |

---

## Methodologically Distinct Pairs (Expected Low Overlap)

These domain pairs have low co-publication because they use fundamentally different research methods (e.g., genetic association studies vs. medical device engineering). Low overlap here does **not** indicate a missed opportunity — it reflects the natural structure of the research landscape.

| Domain 1 | Domain 2 | Gap Score | Joint Pubs | Expected | Note |
|----------|----------|-----------|------------|----------|------|
| Islet Transplant | GWAS / Polygenic | 100.0 | 0 | 1,093 | Surgical transplantation vs. genomic association — fundamentally different methods |
| Islet Transplant | Personalized Nutr | 100.0 | 0 | 375 | Post-transplant nutrition is clinical, not research-overlap territory |
| GWAS / Polygenic | Closed Loop / AP | 100.0 | 0 | 2,985 | Genomics vs. device engineering — no natural intersection |
| GWAS / Polygenic | CGM Technology | 100.0 | 2 | 5,556 | Genomics vs. device engineering (though pharmacogenomics of CGM response could bridge) |
| Treg / CAR-T | CGM Technology | 100.0 | 1 | 2,323 | Immunotherapy vs. device engineering |
| Personalized Nutr | Closed Loop / AP | 100.0 | 0 | 1,025 | Nutrition science vs. device engineering |
| Drug Repurposing | Closed Loop / AP | 100.0 | 0 | 1,008 | Pharmacology vs. device engineering |
| Drug Repurposing | CGM Technology | 100.0 | 0 | 1,877 | Pharmacology vs. device engineering |
| Gene Therapy | CGM Technology | 99.9 | 5 | — | Gene therapy vs. monitoring hardware |

---

## Unclassified Gaps (Require Expert Review)

These domain pairs show high gap scores but have not been classified as either meaningful or methodologically distinct. Domain expert input is needed before prioritization.

| Domain 1 | Domain 2 | Gap Score | Joint Pubs | Expected | Initial Assessment |
|----------|----------|-----------|------------|----------|-------------------|
| Treg / CAR-T | Glucokinase | 100.0 | 0 | 847 | Plausible: immune modulation + beta cell metabolic sensors. Needs expert input. |
| Treg / CAR-T | Personalized Nutr | 100.0 | 0 | 717 | Uncertain: immune-nutrition interaction is real but may be too broad. |
| Beta Cell Regen | Retinopathy | 99.9 | 5 | — | Likely methodological: regeneration is cellular, retinopathy is vascular. |
| Beta Cell Regen | Neuropathy | 99.9 | 2 | — | Possible: shared neurotrophic factors. Needs review. |
| Beta Cell Regen | LADA | 99.9 | 1 | — | Plausible: LADA retains residual beta cells; regen could help. |
| Insulin Resistance | Closed Loop / AP | 99.9 | 3 | — | Meaningful: IR affects insulin dosing algorithms. AID systems don't account for IR variation. |
| Insulin Resistance | Health Equity | 99.9 | 6 | — | Plausible: IR prevalence varies by ethnicity/SES. Under-studied intersection. |
| Autoimmunity T1D | Personalized Nutr | 99.9 | 1 | — | Plausible: dietary triggers of autoimmunity are debated (gluten, cow's milk). |
| Autoimmunity T1D | Health Equity | 99.9 | 3 | — | Meaningful: T1D screening access varies by race/income. |
| Islet Transplant | Microbiome Gut | 99.9 | 1 | — | Possible: immunosuppression alters microbiome; microbiome may affect graft. |
| Epigenetics | Health Equity | 99.9 | 5 | — | Meaningful: environmental exposures driving epigenetic changes vary by SES. |
| Epigenetics | LADA | 99.9 | 1 | — | Plausible: epigenetic triggers for late-onset autoimmunity. |
| Treg / CAR-T | SGLT2 Inhibitors | 99.9 | 3 | — | Uncertain: no obvious mechanistic link. |
| Treg / CAR-T | Drug Repurposing | 99.9 | 1 | — | Plausible: existing immunomodulators could enhance Treg function. |
| SGLT2 Inhibitors | Gestational DM | 99.9 | 12 | — | Meaningful: SGLT2i safety in pregnancy is an open clinical question. |
| Glucokinase | Microbiome Gut | 99.9 | 2 | — | Uncertain: gut metabolites may affect hepatic GK activity. Speculative. |
| Glucokinase | Retinopathy | 99.9 | 4 | — | Possible: GK-mediated glucose sensing in retinal cells. |

---

## Individual Domain Publication Volumes (2020+)

| Domain | Publications | Change vs. Mar 15 | Relative Activity |
|--------|-------------|-------------------|-------------------|
| Prevention / DPP | 75,856 | +849 | ████████████████████ |
| CV Complications | 24,376 | +289 | ██████░░░░░░░░░░░░░░ |
| Insulin Resistance | 18,738 | +220 | ████░░░░░░░░░░░░░░░░ |
| Retinopathy | 15,909 | +176 | ████░░░░░░░░░░░░░░░░ |
| Gestational DM | 14,369 | +173 | ███░░░░░░░░░░░░░░░░░ |
| Nephropathy DKD | 13,293 | +163 | ███░░░░░░░░░░░░░░░░░ |
| GLP-1 Agonists | 11,958 | +226 | ███░░░░░░░░░░░░░░░░░ |
| Metabolomics | 11,735 | +131 | ███░░░░░░░░░░░░░░░░░ |
| AI / ML Predict | 10,300 | +221 | ██░░░░░░░░░░░░░░░░░░ |
| Microbiome Gut | 9,691 | +146 | ██░░░░░░░░░░░░░░░░░░ |
| Youth Diabetes | 7,590 | +83 | ██░░░░░░░░░░░░░░░░░░ |
| Epigenetics | 7,109 | +82 | █░░░░░░░░░░░░░░░░░░░ |
| SGLT2 Inhibitors | 6,934 | +95 | █░░░░░░░░░░░░░░░░░░░ |
| CGM Technology | 6,181 | +98 | █░░░░░░░░░░░░░░░░░░░ |
| GWAS / Polygenic | 4,994 | +53 | █░░░░░░░░░░░░░░░░░░░ |
| Proteomics | 4,456 | +80 | █░░░░░░░░░░░░░░░░░░░ |
| Autoimmunity T1D | 4,340 | +50 | █░░░░░░░░░░░░░░░░░░░ |
| Remission T2D | 4,022 | +42 | █░░░░░░░░░░░░░░░░░░░ |
| Neuropathy | 2,986 | +29 | ░░░░░░░░░░░░░░░░░░░░ |
| Gene Therapy | 2,136 | +30 | ░░░░░░░░░░░░░░░░░░░░ |
| Health Equity | 1,852 | +22 | ░░░░░░░░░░░░░░░░░░░░ |
| Closed Loop / AP | 1,784 | +13 | ░░░░░░░░░░░░░░░░░░░░ |
| Multi-Omics | 1,428 | +43 | ░░░░░░░░░░░░░░░░░░░░ |
| Beta Cell Regen | 1,387 | +12 | ░░░░░░░░░░░░░░░░░░░░ |
| Treg / CAR-T | 873 | +12 | ░░░░░░░░░░░░░░░░░░░░ |
| Glucokinase | 822 | +6 | ░░░░░░░░░░░░░░░░░░░░ |
| Personalized Nutr | 589 | +10 | ░░░░░░░░░░░░░░░░░░░░ |
| Drug Repurposing | 570 | +15 | ░░░░░░░░░░░░░░░░░░░░ |
| LADA | 541 | +6 | ░░░░░░░░░░░░░░░░░░░░ |
| Islet Transplant | 239 | +1 | ░░░░░░░░░░░░░░░░░░░░ |

**Notable growth (19 days):** GLP-1 Agonists (+226) and AI/ML (+221) show the fastest absolute growth, reflecting the post-Foundayo and AI-in-medicine surges. Multi-Omics grew +43 from a small base (+3.1%), making it the fastest-growing domain by percentage.

---

## How to Use This Analysis

1. **Meaningful gaps** are starting points for literature synthesis. For each, search PubMed with combined terms to verify the gap is real (not a terminology artifact).
2. **Methodologically distinct** pairs can be deprioritized unless a specific bridging mechanism is identified.
3. **Unclassified gaps** need expert review before action. Submit to domain researchers for classification.
4. All gap scores should be validated against systematic review databases (Cochrane, PROSPERO) to confirm no existing reviews cover the intersection.

---

## Validation Status

| Aspect | Level | Notes |
|--------|-------|-------|
| Data source | PubMed E-utilities | Covers MEDLINE-indexed literature; misses preprints, grey literature |
| Gap scoring method | Published formula | Geometric mean normalization is standard in bibliometric analysis |
| Gap classifications | BRONZE | Single analyst classification; requires expert validation |
| Individual domain counts | Verifiable | Can be independently reproduced by querying PubMed directly |
| Temporal scope | 2020+ | Recent literature only; historical gaps may differ |
| Comparison to prior run | Validated | Mar 15 → Apr 3: top 5 gaps stable; domain volumes consistent |

---

*Generated by Diabetes Research Hub — Literature Gap Analysis (Enriched)*
*Methodology: Research Doctrine v1.1 — Triple-source validation pending for gap classifications*
